WHAT IS NEVOME?
At DermTech, we believe in cutting the uncertainty, not the patient. Nevome is the first test to non-invasively identify high-risk pigmented lesions by analyzing known DNA mutation risk factors for melanoma. This revolutionary new test uses tissue samples collected with an adhesive patch. When combined with the Pigmented Lesion Assay (PLA) gene expression analysis, the additional DNA mutation analysis can provide a more complete picture of lesions or moles at high risk for melanoma. Nevome analyzes mutations in BRAF, NRAS and TERT promoter genes, while the PLA analyzes the gene expression of LINC00518 and PRAME.
DNA MUTATION ANALYSIS
The analysis of DNA risk factors includes partial exon sequencing for hotspot mutations of the BRAF, NRAS, and TERT genes. Mutations of these genes are found in early stage (MIS / Stage 1) primary cutaneous and metastatic melanoma. Cancer transformation, as in melanoma, is associated with mutations in specific genes known as driver mutations. Driver mutations in nevi can be viewed as risk factors for melanoma and may help identify lesions at risk for cancer at the earliest stages. Double mutation lesions are also associated with histologic criteria of progression including mitotic counts and ulceration. Nevome includes these mutations to identify high risk lesions.
THE DNA ADVANTAGE
Nevome identifies hotspot driver mutations in BRAF, NRAS and TERT genes found in melanoma. Mutations of these genes are found in early stage (MIS / Stage 1) primary cutaneous and metastatic melanoma. Nevome includes these mutations to identify high risk lesions. The combined RNA/DNA test has a sensitivity of 97% and a negative predictive value of >99%.1
WHEN SHOULD I TEST?
Nevome can be ordered if the PLA test is positive. Nevome and the PLA are intended for use on pigmented skin lesions, clinically suspicious for melanoma. DermTech’s Nevome helps to facilitate the early detection of melanoma skin cancer.
At DermTech, We Love Making a Difference in Patient Care
“Recently, I had a young female patient with a mildly suspicious lesion on the back of her neck. Given the age of the patient, I am not sure I would have done an invasive biopsy on this lesion. Since I have the non-invasive PLA test in my office, I chose to do that first. The test came back positive for both LINC and PRAME and substantiated the need for a surgical biopsy. The histopathology showed a 1.1mm SS MM. You all may have saved her! The lesion didn’t look that bad, so I may have just photographed it and regularly monitored it. Having the PLA gave me an additional option to obtain objective information to guide my clinical treatment decision.
Wanting further information, I requested DermTech’s Nevome DNA reflex test be performed. The Nevome test detected DNA hot spot driver mutations TERT promoter and BRAF. The additional information provided by Nevome guided my follow-up protocol with this patient to bring her in for more frequent skin checks as well as to perform skin checks on her family members.”
Dr. Brook Brouha, MD, Ph.D.
Board Certified Dermatologist and Dermatopathologist
2018 AAD Abstract
Ferris L, et al. Clinical Abstract 2018 IID.
Cancer Genome Atlas Network. Genomic Classification of Cutaneous Melanoma. Cell. 2015 Jun 18;161(7):1681-96. doi: 10.1016/j.cell.2015.05.044. PubMed PMID: 26091043
Shain AH, Yeh I, Kovalyshyn I, Sriharan A, Talevich E, Gagnon A, Dummer R, North J, Pincus L, Ruben B, Rickaby W, D’Arrigo C, Robson A, Bastian BC. The Genetic Evolution of Melanoma from Precursor Lesions. N Engl J Med. 2015 Nov 12;373(20):1926-36. doi: 10.1056/NEJMoa1502583. PubMed PMID: 26559571.
Haqq C, Nosrati M, Sudilovsky D, Crothers J, Khodabakhsh D, Pulliam BL, Federman S, Miller JR 3rd, Allen RE, Singer MI, Leong SP, Ljung BM, Sagebiel RW, Kashani-Sabet M. The gene expression signatures of melanoma progression. Proc Natl Acad Sci U S A. 2005 Apr 26;102(17):6092-7. Epub 2005 Apr 15. PubMed PMID: 15833814